X‐linked lymphoproliferative syndrome associated with Epstein–Barr virus encephalitis and lymphoproliferative disorder

Abstract

Key Clinical Message When treating patients with EBV encephalitis, the possibility of XLP should be considered. Once the diagnosis of XLP is made, aggressive treatment such as rituximab, and other immunosuppressive agents are desired for rapid transition to HSCT.

Keywords

• Epstein–Barr virus
• hemophagocytic Lymphohistiocytosis
• lymphoproliferative disorders
• rituximab
• X‐linked lymphoproliferative syndrome